![Dominick DiSabatino Healthcare Lawyer Sheppard Mullin](https://www.natlawreview.com/sites/default/files/styles/author_profile/public/images/46793_directory.jpg?itok=zASxO2fx)
Dominick DiSabatino is a partner on the Life Sciences team in the firm's Washington, D.C. office.
Areas of Practice
Dominick’s practice focuses on complex FDA and healthcare regulatory, compliance and legal matters in the life sciences industry. Drawing from in-house secondments with clients of various growth stages, Dominick counsels pharmaceutical, biotechnology, cosmetics and medical device companies on critical business decisions spanning the entire product life cycle, from research and development to product launch and commercialization.
Dominick offers clients a deep knowledge of advertising and promotion of FDA-regulated products, organizational OIG compliance programs, labeling review and approval strategies, managed markets and payer interactions and privacy/data security concerns. He also advises his clients on matters regarding commercial contracting and supply chain logistics, clinical trial agreements, federal transparency obligations and interactions with FDA such as post-market adverse event and product complaint reporting, facility inspections and Form 483s. With his background in intellectual property law, Dominick identifies client issues related to patents, trademarks, copyrights and trade secrets.
Dominick is committed to pro bono service. He has counseled nonprofit organizations focused on health care integration and optimization and post-incarceration reentry programs. He also represented New York City's senior citizens in housing disputes and provided free speech advice for press operations in Africa.
More Legal and Business Bylines From Dominick DiSabatino
- LDT Final Rule Series: Part 1 – Rule Overview - (Posted On Thursday, June 06, 2024)
- LDT Final Rule Series: Part 2 – Response to the Rule - (Posted On Thursday, June 06, 2024)
- FDA Gets Technical on HCT/P Rules in Warning Letter to Human Tissue Company - (Posted On Friday, May 31, 2024)
- OIG Issues Favorable Advisory Opinion Regarding Patient Assistance Funds - (Posted On Wednesday, May 08, 2024)
- FDA Makes Good on Its Promise to Regulate Laboratory-Developed Tests - (Posted On Tuesday, April 30, 2024)
- Time to Refresh? FDA Issues Draft Guidance on Key Information and Informed Consent - (Posted On Tuesday, March 19, 2024)
- Oregon Prescription Drug Price Transparency Act in Limbo - (Posted On Saturday, March 09, 2024)
- FDA’s Office of Prescription Drug Promotion Issues Its First Untitled Letter of the Year to Novartis for Misleading Statement Relating to KISQALI® - (Posted On Tuesday, February 06, 2024)
- OIG Permits Medical Device Manufacturer’s Cost-Sharing Subsidies for Medicare Beneficiaries in Clinical Trial - (Posted On Wednesday, January 31, 2024)
- 2024 Top-of-Mind Issues for Life Sciences Companies - (Posted On Monday, January 29, 2024)